Trust's refusal to fund trastuzumab was “arbitrary”BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7544.747 (Published 30 March 2006) Cite this as: BMJ 2006;332:747
- Clare Dyer, legal correspondent
An NHS trust that refused to pay for a woman with breast cancer to be treated with the monoclonal antibody trastuzumab (Herceptin) was accused of decision making that was “arbitrary in the extreme,” in the Court of Appeal this week.
David Pannick QC, counsel for Ann Marie Rogers, made the accusation as he launched an appeal against a High Court ruling last month upholding the stand taken by Swindon Primary Care Trust.
Ms Rogers, a 54 year old mother of three with HER2 breast cancer, has likened the trust's refusal to fund the £22 000 (€32 000; …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial